Related Experiment Videos
RNA viruses as virotherapy agents
1Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA. sjr@mayo.edu
Abstract:
RNA viruses are rapidly emerging as extraordinarily promising agents for oncolytic virotherapy. Integral to the lifecycles of all RNA viruses is the formation of double-stranded RNA, which activates a spectrum of cellular defense mechanisms including the activation of PKR and the release of interferon. Tumors are frequently defective in their PKR signaling and interferon response pathways, and therefore provide a relatively permissive substrate for the propagation of RNA viruses. For most of the oncolytic RNA viruses currently under study, tumor specificity is either a natural characteristic of the virus, or a serendipitous consequence of adapting the virus to propagate in human tumor cell lines. Further refinement and optimization of these oncolytic agents can be achieved through virus engineering. This article provides a summary of the current status of oncolytic virotherapy efforts for seven different RNA viruses, namely, mumps, Newcastle disease virus, measles virus, vesicular stomatitis virus, influenza, reovirus, and poliovirus.
Insights
RNA viruses show promise for oncolytic virotherapy, targeting cancer by exploiting tumor-specific defects in cellular defenses. Engineering these viruses enhances their tumor specificity and therapeutic potential.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- RNA viruses are emerging as potent oncolytic virotherapy agents.
- Double-stranded RNA formation activates cellular defenses (PKR, interferon).
- Tumors often have defective PKR and interferon pathways, promoting viral replication.
Purpose of the Study:
- To summarize the current status of oncolytic virotherapy using RNA viruses.
- To highlight seven specific RNA viruses under investigation for cancer treatment.
Main Methods:
- Review of current research on oncolytic RNA viruses.
- Analysis of viral characteristics and tumor interactions.
- Discussion of virus engineering for enhanced specificity.
Main Results:
- Tumor cells are often permissive to RNA virus replication due to immune pathway defects.
- Natural or adapted tumor specificity is observed in many oncolytic RNA viruses.
- Virus engineering offers a route for optimizing oncolytic agents.
Conclusions:
- Oncolytic RNA virotherapy is a rapidly developing field with significant therapeutic potential.
- Seven distinct RNA viruses are being explored for their oncolytic capabilities.
- Further refinement through genetic engineering is key to maximizing efficacy.